Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
W., Leite-Moreira, A
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
Hydration and Sleep: Supporting Your Journey Adequate hydration and quality sleep play crucial roles in weight loss
This hormone regulates blood sugar, slows stomach emptying, and signals fullness to your brain
Williams, a 23-time Grand Slam champion, told Elle magazine that after having her second child in 2023, she lost weight within two weeks, but no matter what she did after that, she couldnt lose more
Available at: Ozempic and Wegovy are registered trademarks of Novo Nordisk
